Assessing Condition‐Specific Adverse Event Profiles of Modafinil for Labelled and Off‐Label Uses: A Systematic Review and Meta‐Analysis
Basic & Clinical Pharmacology & Toxicology · 2026
DOI: 10.1111/bcpt.70147 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Jaehee Jung und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea. Hauptthemen laut MEDLINE: Modafinil, Off-Label Use, Wakefulness-Promoting Agents, Benzhydryl Compounds. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Modafinil is approved for excessive daytime sleepiness in narcolepsy, obstructive sleep apnoea (OSA), and shift work sleep disorder (SWSD), but its widespread off‐label use raises safety concerns. We evaluated the risk of adverse events (AEs) associated with both labelled and off‐label use of modafinil. A systematic search of PubMed, Embase, and Cochrane identified 54 studies that met the inclusion criteria. In labelled uses, narcolepsy patients had significantly elevated risks of diarrhoea (risk ratio [RR]: 2.16, 95% confidence interval [CI]: 1.06–4.41) and nausea compared to those with placebo (RR: 2.44, 95% CI: 1.05–5.72). OSA/hypopnea syndrome patients had higher risks of insomnia (RR: 5.82), anxiety/nervousness (RR: 3.26), and headache (RR: 1.92). SWSD patients had elevated risks of insomnia (RR: 4.09), anxiety/nervousness (RR: 3.85), and nausea (RR: 2.93). Among off‐label users, patients with attention deficit hyperactivity disorder had higher risks of insomnia (RR: 4.97) and decreased appetite (RR: 4.21). Patients with major depressive disorder showed higher risks of anxiety/nervousness (RR: 1.95). While modafinil users share common AEs, specific risks vary across patient groups. Our findings on condition‐specific AE profiles would support cautious prescribing of modafinil and careful consideration of alternative treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea.
- Department of Pharmaceutical Medicine & Regulatory Sciences, College of Medicine and College of Pharmacy, Yonsei University, Incheon, South Korea.
- Graduate Program of Industrial Pharmaceutical Science, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea.
- College of Pharmacy, Ewha Womans University, Seoul, South Korea.
- National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea.
ORCID-Profile: Jihyun Kang, Ah-Young Kim
Zitieren
APA
Jung, J., Youm, J., Kang, J., Kim, A. Y., Suh, J. K., & Kang, H. Y. (2026). Assessing Condition‐Specific Adverse Event Profiles of Modafinil for Labelled and Off‐Label Uses: A Systematic Review and Meta‐Analysis. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70147
Vancouver
Jung J, Youm J, Kang J, Kim AY, Suh JK, Kang HY. Assessing Condition‐Specific Adverse Event Profiles of Modafinil for Labelled and Off‐Label Uses: A Systematic Review and Meta‐Analysis. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70147
BibTeX
@article{Jung2026,
author = {Jung, Jaehee and Youm, Jaeyoon and Kang, Jihyun and Kim, Ah-Young and Suh, Jae Kyung and Kang, Hye-Young},
title = {Assessing Condition‐Specific Adverse Event Profiles of Modafinil for Labelled and Off‐Label Uses: A Systematic Review and Meta‐Analysis},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
doi = {10.1111/bcpt.70147}
}
EUVIMED